ORCiD
Adam M. Kaye: 0000-0002-7224-3322
Document Type
Article
Publication Title
Health Psychology Research
ISSN
2420-8124
Volume
10
Issue
5
DOI
10.52965/001c.38536
First Page
38536
Last Page
38536
Publication Date
1-1-2022
Abstract
An intranasal formulation of midazolam, Nayzilam, has been FDA-approved to treat intermittent, stereotypic episodes of frequent seizure activity. Nayzilam is easy to administer and can quickly treat seizures that occur outside of the hospital. The intra-nasal route of administration allows non-medical personal to administer the drug which makes it more accessible and user-friendly in the event of a seizure. Many studies have indicated quick cessation of seizures with Nayzilam compared to rectal diazepam, which has been the standard of care treatment. Nayzilam has been proven to be safe and effective for acute seizures in children, deeming it a revolutionary alternative in times where intravenous administration is not possible.
Recommended Citation
Cornett, E. M.,
Nemomsa, M. A.,
Turbeville, B.,
Busby, M. A.,
Kaye, J. S.,
Kaye, A. J.,
Choi, J.,
Ramírez, G. F.,
Varrassi, G.,
Kaye, A. M.,
Kaye, A. D.,
Wilson, J.,
&
Ganti, L.
(2022).
Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review..
Health Psychology Research, 10(5), 38536–38536.
DOI: 10.52965/001c.38536
https://scholarlycommons.pacific.edu/phs-facarticles/654
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Chemicals and Drugs Commons, Pharmacy and Pharmaceutical Sciences Commons
